Replies to Is this drug specific to the KRAS mutation? Is it being also tested on non-KRAS patients? | Mayo Clinic Connect

← Return to Anyone else on Daraxonrasib (RMC-6236)?

Discussion

Anyone else on Daraxonrasib (RMC-6236)?

Pancreatic Cancer | Last Active: May 30 9:26am | Replies (26)

Comment receiving replies

@alanbeavfan

Is this drug specific to the KRAS mutation? Is it being also tested on non-KRAS patients?

Jump to this post

Replies to "Is this drug specific to the KRAS mutation? Is it being also tested on non-KRAS patients?"

strongone21 | @strongone21 | May 12 9:39pm

@alanbeavfan this is only for KRAS mutations from what I know.

mcoplien | @mcoplien | May 26 3:33pm

@alanbeavfan Yes it is specific for the KRAS mutation. We are also waiting for it. My husband has stage four pancreatic cancer, reoccurring after he was stage 1 and had surgery and 6 month of 5FU. Gemcitabine/Abraxane stopped working, so he is back on 5FU while we wait for the approval.